BIOTECH INVE$T

DOWNLOAD AGENDA

 

Biotech Inve$t, Tuesday 19 March 2019

08:45

Organiser’s welcome Remarks

Opening Keynote Plenary

David Lane
09:00

Going global and keeping it local: Is biotech innovation sustainable in Asia?

In this keynote presentation, Sir David Lane, one of the key scientists credited on the discovery of cancer gene p53, a gene which mutation cause near 50% of all human cancer, will share his view on how biomedical sciences have developed in Singapore, Japan and the remaining APAC region, and prospects for Asian biotech and pharma industry.
Byung-Geon (BG) Rhee
09:20

Looking east: Integrating Asia into the global era of innovative medicine

Panel discussion
09:40

Pharma 4.0: Women health & Femtech as the next focus

Women’s health goes beyond mother & childcare. For instance, women has a higher risk of cardiovascular diseases compared to men, hence there is a need to invest more on addressing the biological differences in mainstream disease studies to ensure a more effective, personalised treatment. In addition, big data & AI application on female subjects may also differ from male subjects, prompting a need to investigate how studies should be developed differently in the future. This panel brings experts to debate and discuss how femtech is shaping to be the next global pharma focus and the new areas of focus in women's healthcare.
10:20

Speed networking & Networking Refreshment

Carrie Hillyard
Biotech Inve$t
11:15

Chair's opening remarks

Petcha Kucha
Biotech Inve$t
12:00

Biotech Pitch

10 minutes per company
Poh Loong Soong, Founder, M.D., CEO, Ternion Biosciences Pte. Ltd
12:40

Exhibition Visit & Networking Lunch

Biotech Inve$t
14:10

Chair’s opening remarks

15:40

Exhibition Visit & Networking Refreshments

Panel discussion
17:40

Networking Cocktail & End of Conference Day 1

last published: 26/Sep/18 03:35

Biotech Inve$t, Wednesday 20 March 2019

08:45

Organiser’s welcome Remarks

08:50

Chairman’s opening Remarks

09:00

The path to personalised medicine: Key developments

Everyone knows the potential benefits of personalised medicine, but how do we get there? Finding and better defining disease through biomarkers and more accurate diagnostics. Targeted therapeutics to leverage new and emerging diagnostic capabilities. Personalized Medicine to Real-Time Medicine. How to drive success across industry and clinical implementation in an economic manner. This presentation discusses various strategies and key considerations to drive the symbiosis between academia, industry and clinical medicine to drive vastly improved patient outcomes.
Nadia Suttikulpanich
09:20

Disrupt before being disrupted: Using digital tech to connect to previously uneconomic chronic disease customers

10:20

Roundtable discussion

Table 1 Working with clinical outsourcing partners: Risk management and prevention

Table 2 Fostering commercial partnerships to tap on emerging APAC markets

Table 3 Regulatory collaboration and opportunities in more efficient drug development

Table 4 Strategies in making drugs more affordable and accessible to patients in developing countries

Table 5 Universal healthcare- Is it really costly?

Table 6 A convergent approach: Tapping on western expertise to serve Asia population

Table 7 Precision to personalised medicine- How do we get there?

Table 8 Leveraging blockchain technology in making clinical trials more transparent and efficient

Table 9: Data Science in practice: How can sales reps and MSLs use Big Data?

Table 10: The Singapore biotech ecosystem – What comes after the Inflexion?

11:00

Exhibition Visit & Networking Refreshments

Petcha Kucha
Biotech Inve$t
11:00

Biotech Pitch

10 minutes per company
13:00

Exhibition Visit & Networking Lunch

Petcha Kucha
Biotech Inve$t
13:40

Biotech Pitch

10 minutes per company
16:30

End of Phar-East 2019

last published: 26/Sep/18 03:35

 

 

DOWNLOAD PROSPECTUS

 

 

For speaking, sponsorship and exhibition opportunities contact jonathan.mottram@terrapinn.com
Tel: +65 6322 2738